Skip to main content

Enzamaría Fidilio Meli

Institutions of which they are part

Predoctoral researcher
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Enzamaría Fidilio Meli

Institutions of which they are part

Predoctoral researcher
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Projects

¿CONOCER LA PREDISPOSICIÓN GENETICA DEL PACIENTE CON OBESIDAD AYUDA A MEJORAR LA EFICACIA DE LA CIRUGÍA BARIÁTRICA?

IP: -
Collaborators: Marta Comas Martínez, Enzamaría Fidilio Meli
Funding agency: Instituto de Salud Carlos III
Funding: 117370
Reference: PI21/00462
Duration: 01/01/2022 - 30/06/2026

ROL DE LA APELINA EN LA ENFERMEDAD RENAL DIABÉTICA: DEL RATÓN AL HUMANO

IP: Maria Jose Soler Romeo
Collaborators: Marina Lopez Martinez, Jordi Vilardell Vilà, Irene Martinez Diaz, Sheila Bermejo Garcia, Vicent Muñoz Vaño, Carmen Llorens Cebriá, M Antonieta Azancot Rivero, Enzamaría Fidilio Meli, Juan Carlos León Román, Sara Nuñez Delgado
Funding agency: Instituto de Salud Carlos III
Funding: 190000
Reference: PI24/01510
Duration: 01/01/2025 - 31/12/2027

Utilidad del TAC abdominal e inteligencia artificial para la evaluación de la composición corporal y condición metabólica en sujetos con obesidad: estudio FLASH

IP: Andreea Ciudin Mihai
Collaborators: Manuel Escobar Amores, Nuria Roson Gradaille, Fiorella Ximena Palmas Candia, Aitor Rodriguez Martinez, Marta Comas Martínez, Enzamaría Fidilio Meli
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 431460
Reference: CPP2023-010524
Duration: 01/11/2024 - 30/10/2027

Ministerio de Ciencia

Mechanisms of metabolic adaptation after weight loss in obesity. Clinical phenotyping and therapeutic approach.

IP: Andreea Ciudin Mihai
Collaborators: Cristina Gamez Cenzano, Eduard Rodenas Alesina, Ana Marti Delgado, Fiorella Ximena Palmas Candia, Bruno García del Blanco, Ana Belén Méndez Fernández, Ana Maria Ciscar Bellés, Aleix Olivella San emeterio, Marta Comas Martínez, Alvaro Calabuig Goena, Enzamaría Fidilio Meli, Marco Tomasino
Funding agency: Instituto de Salud Carlos III
Funding: 165000
Reference: PI23/01209
Duration: 01/01/2024 - 31/12/2026

Related news

The work represents a paradigm shift in the clinical approach to this chronic, multifactorial disease, based on the clinical context of each patient and not only on weight loss.

The results of a phase 3 clinical trial show that orforglipron reduces body weight by an average of 11% and improves cardiovascular risk factors.

Dr. Maria Llorián-Salvador, from the Diabetes and Metabolism Research Group at VHIR, is leading this project to identify new therapies for this inherited disease that causes progressive vision loss.

Related professionals

Veronica Lopez Diego

Veronica Lopez Diego

Predoctoral researcher
Peripheral Nervous System
Read more
Victoria López Craver

Victoria López Craver

Psychiatry, Mental Health and Addictions
Read more
Montse Perez Fernandez

Montse Perez Fernandez

Research technician
Neurodegenerative Diseases
Read more
Samuel López Maza

Samuel López Maza

Predoctoral researcher
Research Group on Status Epilepticus and Acute Seizures
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.